Sectors:
Locations:
Min Investment:
Max Investment:
Target Investment:
2006
2021
2015 - 2021
2014 - 2015
2013 - 2014
2011 - 2013
2009 - 2011
2008 - 2009
2006 - 2008
2021
2021
SpliceBio is a biotechnology company exploiting Protein Splicing to develop the next generation of gene therapies. Our platform is based on technology developed in the Muir Lab at Princeton University after more than 20 years of pioneering intein and protein engineering research.
2020
Rappta Therapeutics is a late preclinical stage biopharmaceutical company. We are working on a first-in-class series of anti-cancer molecular glues that reactivate a key tumor suppressor, protein phosphatase 2A (PP2A).
2019
Vivet Therapeutics is a clinical-stage emerging biotechnology company developing novel gene therapy treatments for rare, inherited metabolic diseases.
2022
The UZH Life Sciences Fund (LSF) provides early financing for life sciences, biotech and med tech spin-offs whose business ideas are based on intellectual property resulting from research done at the University of Zurich. The aim is to accelerate the development process of such spin-offs in the early phase of their life cycle (when fund raising can be long and/or difficult), and thus accelerate the transfer of UZH research findings into practice, which ultimately benefits patients and the public at large.
2020 - 2022
2017 - 2020
2019 - 2020
2019 - 2020
Binx Health is creating new categories of healthcare solutions that put on-demand testing where people need it most. With its proprietary, desktop, PCR-based point-of-care testing platforms and consumer digital offerings, Binx is redefining "convenient care" for the modern consumer.
2017 - 2019
2017 - 2019
A pioneering therapeutic approach harnessing the power of protein aggregation.
1999 - 2001
1999 - 2001
1995 - 1998
1995 - 1998
Cardiovascular Surgery